STS Summer Series - SAVR vs. TAVR: Controversial Cases and Insights from the Experts

Nearly 20 years since the first transcatheter aortic valve replacement (TAVR) was performed, the feasibility and effectiveness of the minimally invasive procedure have consistently been substantiated by an accumulation of rigorous, evidence-based clinical experience. With simplification of the technique, improvements in valve design, and expanded indications for patients, should TAVR replace surgical aortic valve replacement (SAVR) as the primary treatment for aortic stenosis (AS)?

In this STS Summer Series webinar, Gorav Ailawadi, MD, MBA, and Tsuyoshi Kaneko, MD, spoke with other SAVR/TAVR experts—cardiothoracic surgeons and cardiologists—about different approaches to AS treatment, especially in patients with:

  • Bicuspid aortic valve
  • Failed surgical bioprosthesis
  • Small annulus 
  • Concomitant coronary disease

This episode was supported by Medtronic.

The episode is also available as a podcast.

Gorav Ailawadi, MD, MBA
University of Virginia
Charlottesville, VA

Tsuyoshi Kaneko, MD
Harvard Medical School, Brigham and Women’s Hospital
Boston, MA

Vinayak N. Bapat, MD
NewYork-Presbyterian/Columbia University Medical Center
New York, NY

Adam B. Greenbaum, MD
Emory Healthcare
Atlanta, GA

Molly A. Szerlip, MD
Baylor Scott & White Health
Plano, TX

Vinod H. Thourani, MD
Piedmont Heart Institute
Atlanta, GA